期刊
ONCOTARGETS AND THERAPY
卷 5, 期 -, 页码 391-401出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S38403
关键词
beta-adrenergic signaling; cancer; beta-blockers; progression; metastasis; angiogenesis
资金
- National Natural Science Foundation of China [81071903, 81072069]
- Key Clinical Discipline of the Ministry of Health [201043941]
- Mingdao Project of Fudan University
beta-adrenergic signaling modulates key signaling pathways that are important for tumor-promoting processes, and numerous mechanisms of action have been elucidated. Preclinical studies have demonstrated that beta-adrenergic antagonists, or beta-blockers, can block multiple fundamental biologic processes underlying the progression and metastasis of tumors, including the inhibition of cell proliferation, migration, invasion, resistance to programmed cell death, and tumor angiogenesis and metastasis. Human pharmacoepidemiologic studies suggest that beta-blockers have a role in inhibiting cancer progression and metastasis in combination with standard therapies. Furthermore, a number of prospective studies have demonstrated that beta-blockers are effective at halting infantile hemangioma growth. These findings shed light on the novel perspective of using beta-blockers as a class of potential antitumor agents in clinical oncology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据